Commodore Capital LP Cardiff Oncology, Inc. Transaction History
Commodore Capital LP
- $1.02 Billion
- Q1 2025
A detailed history of Commodore Capital LP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Commodore Capital LP holds 5,384,616 shares of CRDF stock, worth $21.4 Million. This represents 1.66% of its overall portfolio holdings.
Number of Shares
5,384,616
Previous 5,384,616
-0.0%
Holding current value
$21.4 Million
Previous $23.4 Million
27.65%
% of portfolio
1.66%
Previous 2.34%
Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
125Shares Held
29MCall Options Held
900KPut Options Held
234K-
Vanguard Group Inc Valley Forge, PA3.12MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$10.5 Million0.0% of portfolio
-
Blair William & CO Chicago, IL1.75MShares$6.97 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$5.75 Million0.01% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$5.74 Million3.15% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $172M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...